Patents by Inventor Claus Rudolf Steinborn

Claus Rudolf Steinborn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the treatment of diabetes
    Patent number: 7122357
    Abstract: The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: October 17, 2006
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Suntje Sander-Struckmeier, Claus Rudolf Steinborn, Martin A. Rudmann, Diethard Schwanitz, Friederike Henniges
  • Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and methods of treatment relating to anti-arrhythmic events
    Patent number: 7087620
    Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: August 8, 2006
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Matthias Straub, Johannes Wilhelmus Catharine Maria Jansen, Michiel Henricus de Vries, Claus Rudolf Steinborn, Werner Cautreels
  • Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1] nonane compounds and methods of treatment relating to anti-arrhythmic events
    Publication number: 20040152716
    Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.
    Type: Application
    Filed: November 18, 2003
    Publication date: August 5, 2004
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Matthias Straub, Johannes Wilhelmus Catharine Maria Jansen, Michiel Henricus de Vries, Claus Rudolf Steinborn, Werner Cautreels
  • Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
    Publication number: 20030125349
    Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.
    Type: Application
    Filed: January 22, 2003
    Publication date: July 3, 2003
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Werner L. M. Cautreels, Claus Rudolf Steinborn, Heinz Guenter Krause, Steven David Caras, Egbertus Hendrikus Evert Biesheuvel, Albertus Hermannus Dirk Plekkenpol
  • Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
    Patent number: 6566369
    Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: May 20, 2003
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Werner L. M. Cautreels, Claus Rudolf Steinborn, Heinz Guenter Krause, Steven David Caras, Egbertus Hendrikus Evert Biesheuvel, Albertus Hermannus Dirk Plekkenpol
  • Method for the treatment of diabetes
    Publication number: 20020061302
    Abstract: The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.
    Type: Application
    Filed: September 17, 2001
    Publication date: May 23, 2002
    Inventors: Suntje Sander-Struckmeier, Claus Rudolf Steinborn, Martin A. Rudmann, Diethard Schwanitz, Friederike Henniges
  • Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
    Publication number: 20020040033
    Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.
    Type: Application
    Filed: July 20, 2001
    Publication date: April 4, 2002
    Inventors: Werner L.M. Cautreels, Claus Rudolf Steinborn, Heinz Guenter Krause, Steven David Caras, Egbertus Hendrikus Evert Biesheuvel, Albertus Hermannus Dirk Plekkenpol